In part two of Pharmaceutical Executive’s interview with LucyRx’s Chief Commercial Officer Susan Thomas, she explores why many employer-sponsored plans still approach GLP-1s through only two lenses, type 2 diabetes and weight loss, even though these medications show promise across a broader range of cardiometabolic conditions.
The article highlights a challenge many employers face: expanding access while managing costs. Thomas says there is a growing need for more targeted benefit strategies that help plan sponsors identify higher-risk members and focus support where they can make the biggest difference.
Share